Skip to main content
Fig. 4 | BMC Cancer

Fig. 4

From: A small molecular agent YL529 inhibits VEGF-D-induced lymphangiogenesis and metastasis in preclinical tumor models in addition to its known antitumor activities

Fig. 4

Effect of YL529 on tumor growth and survival in s. c. model. The mice bearing tumors subcutaneously were treated with YL529 or controls orally. a YL529 resulting in significant tumor growth inhibition; b Recovered tumor weights were significantly smaller in YL529 treated animals; c There was no significant difference of body weight after YL529 treated; d A significant increase in survival in YL529 treated mice was observed (Log-rank). Mean ± SEM, n = 10, *p < 0.05, **p < 0.01

Back to article page